HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP)
What is HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP)?
HAM/TSP is a chronic and progressive disease of the nervous system caused by HTLV-I infection. HTLV-I stands for human T-cell lymphotropic virus type I. This virus infects certain white blood cells and can lead to inflammation of the spinal cord over time.
The condition affects the ability of your spinal cord to send signals between your brain and legs. Most people with HTLV-I infection never develop HAM/TSP. Only about 1 to 4 out of 100 people infected with the virus will develop this neurological disease. The condition typically develops slowly over months to years after initial infection.
HAM/TSP is more common in certain regions including Japan, the Caribbean, South America, and parts of Africa. In the United States, the condition is relatively rare. Understanding your risk and getting tested if you have symptoms can help you work with your doctor to manage the disease early.
Symptoms
- Weakness in both legs that gets worse over time
- Stiffness or spasticity in the leg muscles
- Difficulty walking or maintaining balance
- Lower back pain that may radiate down the legs
- Bladder problems including urgency or incontinence
- Constipation or other bowel control issues
- Numbness or tingling in the legs and feet
- Sexual dysfunction
- Muscle cramps or spasms in the legs
Symptoms usually develop gradually over months or years. Some people may have mild symptoms that progress slowly, while others experience more rapid decline. Early symptoms can be subtle and easy to miss.
Concerned about HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP)? Check your levels.
Screen for 1,200+ health conditions
Causes and risk factors
HAM/TSP is caused by infection with HTLV-I, a virus that spreads through blood, sexual contact, or from mother to child during breastfeeding. The virus infects immune cells and causes ongoing inflammation in the spinal cord. This inflammation damages the myelin, the protective coating around nerve fibers, which disrupts normal nerve signals.
Risk factors include living in or traveling to areas where HTLV-I is common, receiving blood transfusions before screening began, sharing needles, unprotected sex with an infected partner, and being breastfed by an infected mother. Women are 2 to 3 times more likely to develop HAM/TSP than men. The reason most people with HTLV-I never develop HAM/TSP is not fully understood, but genetic factors and immune response may play a role.
How it's diagnosed
Diagnosis of HAM/TSP requires blood tests to detect HTLV-I antibodies, which show that you have been infected with the virus. Your doctor will also perform a neurological exam to check your leg strength, reflexes, and walking ability. An MRI of the spinal cord may show areas of inflammation or damage. A spinal tap may be done to look for antibodies and inflammation in the fluid around your spinal cord.
Specialized testing is needed to diagnose HAM/TSP. If you have symptoms or risk factors, talk to your doctor about appropriate testing. Early diagnosis helps you and your healthcare team create a treatment plan to manage symptoms and slow progression of the disease.
Treatment options
- Corticosteroids to reduce inflammation in the spinal cord
- Interferon alpha to help control viral activity
- Physical therapy to maintain muscle strength and mobility
- Medications for muscle spasticity such as baclofen or tizanidine
- Bladder management with medications or catheterization if needed
- Pain management with appropriate medications
- Assistive devices like canes or walkers to improve safety
- Regular exercise adapted to your ability level
- Occupational therapy to help with daily activities
Treatment focuses on managing symptoms and slowing disease progression. There is currently no cure for HAM/TSP. Working closely with a neurologist who understands this condition is important for the best outcomes.
Frequently asked questions
Scientists do not fully understand why only 1 to 4 percent of people with HTLV-I develop HAM/TSP. Genetic factors, the strength of your immune response, and viral load may all play a role. Women are 2 to 3 times more likely to develop the condition than men. Research continues to explore what triggers the disease in some infected individuals.
Diagnosis requires blood tests to detect HTLV-I antibodies combined with neurological symptoms. Your doctor will perform a physical exam to check reflexes, muscle strength, and walking ability. An MRI of your spine and a spinal tap may be needed to confirm inflammation and rule out other conditions. The presence of HTLV-I antibodies in both blood and spinal fluid supports the diagnosis.
There is currently no cure for HAM/TSP. Treatment focuses on managing symptoms and slowing disease progression. Corticosteroids and interferon alpha may help reduce inflammation and viral activity. Physical therapy, medications for spasticity, and bladder management can improve quality of life. Early diagnosis and treatment may help preserve function longer.
The rate of progression varies widely among individuals. Some people experience slow, gradual worsening over many years. Others may have more rapid decline in walking ability and function. Most people will need assistive devices like canes or wheelchairs within 10 to 20 years of symptom onset. Regular monitoring with your doctor helps track changes and adjust treatment as needed.
HAM/TSP itself is not contagious, but the virus that causes it can spread from person to person. HTLV-I spreads through blood, sexual contact, and breastfeeding. If you have HTLV-I infection, you should take precautions to avoid transmitting the virus. This includes using protection during sex, not sharing needles, and considering formula feeding instead of breastfeeding.
Early signs include subtle weakness in the legs, stiffness when walking, and lower back pain. You may notice that you tire more easily when walking or have trouble climbing stairs. Bladder urgency or mild incontinence can be an early symptom. These signs develop gradually and are easy to dismiss, so see your doctor if you have risk factors for HTLV-I and notice these changes.
Regular physical activity adapted to your ability can help maintain muscle strength and flexibility. Physical therapy exercises are important to prevent muscle tightness and preserve mobility. Eating a balanced diet supports overall health and may help manage bowel function. Staying hydrated and maintaining a healthy weight can reduce stress on your legs and back.
People living in or from endemic regions including Japan, the Caribbean, South America, and parts of Africa have higher risk. Those who received blood transfusions before HTLV-I screening began in the late 1980s may be at risk. People who share needles, have unprotected sex with multiple partners, or were breastfed by infected mothers are also at increased risk. Women with HTLV-I are more likely than men to develop HAM/TSP.
Testing is recommended if you have neurological symptoms and risk factors for HTLV-I infection. This includes people from endemic regions, those with unexplained leg weakness or spasticity, and pregnant women from high-risk areas. If you have a family member with HTLV-I or HAM/TSP, discuss testing with your doctor. Early detection allows for monitoring and prompt treatment if symptoms develop.
HTLV-I is the virus that can cause HAM/TSP, but most people with the virus never develop the disease. HTLV-I infection means you carry the virus, which usually causes no symptoms. HAM/TSP is the neurological disease that occurs when the virus triggers inflammation in your spinal cord. Only a small percentage of infected people develop HAM/TSP, typically years after initial infection.